Goldman Sachs’s Bionano Genomics BNGO Stock Holding History

Goldman Sachs’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-528	Closed	-$947K	–	6580
2021 Q4	$947K	Buy	+528	New	+$1.41M	﹤0.01%	4897

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

CCM

Coldstream Capital Management Bellevue, Washington $8.12B AUM 17.95% 1-Year Est. Return

Goldman Sachs's BNGO Position: Q1 2025 in Review

Goldman Sachs sold out of Bionano Genomics (BNGO) in Q1 2025, closing a stake of 184 shares — an estimated $3.18K sold.

Goldman Sachs first reported a position in BNGO in Q1 2021 and held it in 11 quarters. The position peaked at $3.33M in Q2 2021. 30 funds tracked by Wall St. Rank hold BNGO as of Q1 2025.

Goldman Sachs reported no remaining Bionano Genomics position as of Q1 2025 after selling out during the quarter.
Goldman Sachs sold 184 Bionano Genomics shares in Q1 2025, an estimated $3.18K.
Goldman Sachs first reported a position in Bionano Genomics in Q1 2021 and held it in 11 quarters.
Goldman Sachs's Bionano Genomics position peaked at $3.33M in Q2 2021.
30 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.